Dare Bioscience announced the publication of clinical findings for vaginally-administered tamoxifen
in Clinical and Experimental Obstetrics and Gynecology, an international journal for publication of research focused on the development of new therapeutic interventions for obstetrics and gynecology.
TUESDAY, June 5, 2018 (HealthDay News) -- The addition of ovarian suppression to tamoxifen
is associated with increased survival versus tamoxifen
alone among premenopausal women with breast cancer, according to a study published online June 4 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.
The first is tamoxifen
, to which many breast cancer patients owe their lives.
is a selective estrogen receptor modulator (SERM), which is widely used as hormone therapy for estrogen-receptor-positive breast cancer.
6, 2016) suggests that tamoxifen
(Novaldex[R]), and medications from another class of drugs (aromatase inhibitors) may reduce this risk.
In women diagnosed with breast cancer, taking tamoxifen
and/or aromatase inhibitors reduces the risk of developing cancer in their other breast, according to a study published online Oct.
Valley Cottage, NY, January 01, 2016 --(PR.com)-- Tamoxifen
is an antagonist of the estrogen receptor in breast tissue.
SAN DIEGO -- Researchers at the University of California, San Diego, School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have found that the breast cancer drug tamoxifen
gives white blood cells a boost, better enabling them to respond to, ensnare and kill bacteria in laboratory experiments.
SAN ANTONIO -- Adding ovarian suppression to 5 years of tamoxifen
in women with hormone receptor-positive early breast cancer who remain premenopausal following chemotherapy provides a markedly greater reduction in breast cancer recurrence, compared with standard adjuvant therapy with tamoxifen
alone--and combining ovarian suppression with an aromatase inhibitor instead of tamoxifen
further improves outcomes, Dr.
(trade name Nolvadex) has been hailed as a 'wonder drug' by many physicians (and patients) since it's inception in the 1970's.
In most tamoxifen
research, the studies have lasted for a period of five years, although some benefits continue in years 5 to 10.
Women who have hormone-sensitive breast cancer and who have taken tamoxifen
for 5 years as adjuvant therapy stand to benefit from an additional 5 years of the drug, according to preliminary findings from the Adjuvant Tamoxifen
: Longer Against Shorter (ATLAS) trial.